Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma

VernacularTitle:临床伴随药物对免疫检查点抑制剂治疗尿路上皮癌的影响研究进展
Author: Zhengqin LYU ¹ ; Yuhao ZHAO ¹ ; Yuanyuan GUO ¹ ; Beibei LIU ¹ ; Jianmin LIU ¹
Author Information

1. Department of Urology, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China
Publication Type:Review
Keywords: concomitant medication; immune checkpoint inhibitors; urothelial carcinoma
From: Medical Journal of Peking Union Medical College Hospital 2024;15(2):394-399
CountryChina
Language:Chinese
Abstract: Immune checkpoint inhibitors (ICIs) have been approved for the treatment of urothelial carcinoma(UC). However, the use of antibiotics, proton pump inhibitors, corticosteroids, beta-blockers, metformin, and statin concomitant medications in some patients due to complications during the treatment process may affect the clinical efficacy of ICIs through different pathway, making it difficult for patients to derive clinical benefit or making it more likely to develop drug resistance. In this paper, we present a review of the effects of the above concomitant drugs on ICIs in the treatment of patients with advanced UC, with a view to provide reference for the application of individualized treatment strategies of ICIs in patients with advanced UC.